FLAG (fludarabine, cytosine arabinoside, G-CSF) for refractory and relapsed acute myeloid leukemia

Annals of Hematology

Volumn 73, Issue 6, 1996, Pages 265-271

  Huhmann, I M ^a   Watzke, H H ^a   Geissler, K ^a   Gisslinger, H ^a   Jager U ^a   Knobl P ^a   Pabinger, I ^a   Korninger, L ^b   Mannhalter, C ^b   Mitterbauer, G ^b   Schwarzinger, I ^b   Kalhs, P ^b   Haas, O A ^c   Lechner, K ^a  

^a MEDICAL UNIVERSITY OF VIENNA   (Austria)

^b UNIVERSITY OF VIENNA   (Austria)

^c ST ANNA CHILDREN S HOSPITAL   (Austria)

Author keywords

Acute myeloid leukemia; FLAG; Salvage therapy

Indexed keywords

CYTARABINE; FLUDARABINE; GRANULOCYTE COLONY STIMULATING FACTOR; THROMBOCYTE CONCENTRATE;

ACUTE GRANULOCYTIC LEUKEMIA; ADULT; ANTIBIOTIC THERAPY; ARTICLE; BLOOD TOXICITY; BONE MARROW SUPPRESSION; BRAIN HEMORRHAGE; CANCER COMBINATION CHEMOTHERAPY; CANCER RECURRENCE; CANCER SURVIVAL; CELL COUNT; CLINICAL ARTICLE; CLINICAL TRIAL; CONSTIPATION; DIARRHEA; ERYTHROCYTE TRANSFUSION; FEMALE; HEMATURIA; HUMAN; INFECTION; LEUKEMIA REMISSION; LIVER TOXICITY; MALE; NAUSEA; NEPHROTOXICITY; NEUROTOXICITY; NEUTROPENIA; NEUTROPHIL; PAIN; PRIORITY JOURNAL; PROTEINURIA; THROMBOCYTE TRANSFUSION; VOMITING;

ACUTE DISEASE; ADULT; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BONE MARROW TRANSPLANTATION; CENTRAL NERVOUS SYSTEM DISEASES; CYTARABINE; FEMALE; GRANULOCYTE COLONY-STIMULATING FACTOR; HUMANS; LEUKEMIA, MYELOID; MALE; MIDDLE AGED; NAUSEA; NEUTROPENIA; TREATMENT OUTCOME; VIDARABINE; VOMITING;

EID: 12644313240     PISSN: 09395555     EISSN: None     Source Type: Journal    
DOI: 10.1007/s002770050239     Document Type: Article

References (21)

1. Amadori S, Arcese W, Isacchi G. Meloni G, Pelti MC, Monarca B, Testi AM, Mandelli F (1991) Mitoxantrone, etoposide, and intermediate-dose cytarabine: an effective and tolerable regimen for the treatment of refractory acute myeloid leukemia. J Clin Oncol 9:1210-1214
2. Archimbaud E, Thomas X, Leblond V, Michallet M, Fenaux P, Cordonnier C, Dreyfus F, Troussard X, Jaubert J, Travade P, Troncy J, Assouline D, Fiere D (1995) Timed sequential chemotherapy for previously treated patients with acute myeloid leukemia: long-term follow-up of the etoposide, mitoxantrone, and cytarabine - 86 trial. J Clin Oncol 13:11-18
3. Bishop JF, Matthews JP, Young GA, Szer J, Gillett A, Joshua D, Bradstock K, Enno A, Wolf MM, Fox R, Cobcroft R, Herrmann R, van der Weyden M, Lowenthal RM, Page F, Garson OM, Juneja S (1996) A randomized study of high-dose cytarabine in induction in acute myeloid leukemia. Blood 87:1710-1717
4. Dombret H, Chastang C, Fenaux P, Reiffers J, Bordessoule D, Bouabdallah R, Mandelli F, Ferrant A, Auzanneau G, Tilly H, Yver A, Degos L, for the AML Cooperative Study Group (1995) A controlled study of recombinant human granulocyte colony-stimulating factor in elderly patients after treatment for acute myelogenous leukemia. N Engl J Med 332:1678-1683
5. Estey E, Plunkett W, Gandhi V, et al (1993) Fludarabine and arabinosylcytosine therapy of refractory and relapsed acute myelogenous leukemia. Leuk Lymphoma 9:343-350
6. Estey E, Thall P, Andreeff M, Beran M, Kantarjian H, O'Brien S, Escudier S, Robertson LE, Koller C, Kornblau S, Pierce S, Freireich EJ, Deisseroth A, Keating M (1994) Use of granulocyte colony-stimulating factor before, during, and after fludarabine plus cytarabine induction therapy of newly diagnosed acute myelogenous leukemia or myelodysplastic syndromes: comparison with fludarabine plus cytarabine without granulocyte colony-stimulating factor. J Clin Oncol 12:671-678
7. Fonatsch C, Gudat H, Lengfelder E, Wandt H, Silling-Engelhardt G, Ludwig WD, Thiel E, Freund M, Bodenstien H, Schwieder G, Grüneisen A, Aul C, Schnittger S, Rieder H, Haase D, Hild F (1994) Correlation of cytogenetic findings with clinical features in 18 patients with inv(3)(q21q26) or 1(3;3)(q21;q26). Leukemia 8:1318-1326
8. Gandhi V, Estey E, Keating MJ, et al (1993) Fludarabine potentiates metabolism of cytarabine in patients with acute myelogenous leukemia during therapy. J Clin Oncol 11:116-124
9. Heil G, Hoelzer D, Sanz MA, Lechner K, Liu Yin J, Papa G, Noens L, Ho J, O'Brien C, Matcham J, Barge A (1995) Results of a randomised, double-blind placebo-controlled phaseIII study of filgrastim in remission induction and early consolidation therapy for adults with de-novo acute myeloid leukaemia. Blood 86:267a [Suppl]
10. Herzig R, Wolff S, Lazarus H, Phillips R, Karanes C, Herzig G (1983) High-dose cytosine arabinoside therapy for refractory leukemia. Blood 62:361-369
11. Hiddemann W, Büchner T (1990) Treatment strategies in acute myeloid leukemia (AML). Blut 60:163-171
12. Hiddemann W, Kreutzmann H, Straif K Ludwig WD, Mertelsmann R, Donhuijsen-Ant R, Lengfelder E, Arlin Z, Büchner T (1987) High-dose cytosine arabinoside and mitoxantrone: a highly effective regimen in refractory acute myeloid leukemia. Blood 69:744-749
13. Kaplan EL, Meier P (1958) Nonparametric estimation from incomplete observations. J Am Stat Assoc 53:457-481
14. Keating M, Kantarjian H, Smith T, Estey E, Walters R, Andersson B, Beian M, McCredie K, Freireich E (1989) Response to salvage therapy and survival after relapse in acute myelogenous leukemia, J Clin Oncol 7:1071-1080
15. Mayer RJ, Davis RB, Schiffer CA, Berg DT, Powell BL, Schulman P, Omura GA, Moore JO, McIntyre OR, Frei IIIE (1994) Intensive post-remission chemotherapy in adults with acute myeloid leukemia. N Engl J Med 331:896
16. Refaie FNAI, Milojkovic D, Wong THT, Pagliuca A, Grace R, Mufti GH (1996) FLAG/idarubicin for the treatment of poor-risk myeloid malignancies. Br J Haematol 93 [Suppl 1]:19
17. Seeker-Walker LM, Mehta A, Bain B, on behalf of the UKCCG (1995) Abnormalities of 3q21 and 3q26 in myeloid malignancy: a United Kingdom Cancer Cytogenetic Group study. Br J Haematol 91:490-501
18. Steinmetz HT, Staib P, Glasmacher A, Neufang A, Katay I, Diehl V, Dias Wickramanayake P (1996) Phase II study of idarubicine, fludarabine, ARA-C, and G-CSF (IDA-FLAG) for treatment of refractory, relapsed or secondary acute myeloid leukemia. Br J Haematol 93 [Suppl 2]
19. Thalhammer F, Geissler K, Jäger U, Kyrie PA, Pabinger I, Mitterbauer M, Gisslinger H, Knöbl P, Laczika K, Schneider B, Haas OA, Lechner K (1996) Duration of second complete remission in patients with acute myeloid leukemia treated with chemotherapy: a retrospective single-center study. Ann Hematol 72:216-222
20. Visani G, Tosi P, Zinzani PL, Manfroi S, Ottaviani E, Testoni N, Clavio M, Cenacchi A, Gamberi B, Carrara P, Gobbi M, Tura S (1994) FLAG (fludarabine + high-dose cytarabine + G-CSF): an effective and tolerable protocol for the treatment of "poor-risk" acute myeloid leukemias. Leukemia 8:1842-1846
21. Willemze R, Fibbe W, Zwaan F (1983) Experience with intermediate and high-dose cytosine arabinoside in refractory acute leukemia. Oncologia 6:200-204